Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer.
AffiliationCancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractEpidermal growth factor receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) gene rearrangement in advanced non-small cell lung cancer (NSCLC) represent the two oncogenic events with an impact on current clinical practice. EGFR tyrosine kinase inhibitors (TKIs) and crizotinib are the standard of care for the treatment of EGFR mutant and ALK gene rearranged advanced NSCLC patients. Unfortunately, despite initial clinical benefit, acquired resistance to EGFR-TKIs or crizotinib usually develops after an average of 10-12 months of treatment. The aim of this review is to describe the mechanisms of resistance to first/second generation EGFR-TKIs and crizotinib. In particular, we focus on strategies to overcome resistance due to secondary EGFR T790M mutation and mutations of the ALK domain.
CitationOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. 2016, 8 (3):176-87 Ther Adv Med Oncol
JournalTherapeutic Advances in Medical Oncology
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
- Authors: Shea M, Costa DB, Rangachari D
- Issue date: 2016 Apr
- Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
- Authors: Dong X, Fernandez-Salas E, Li E, Wang S
- Issue date: 2016 Mar
- Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application.
- Authors: Maione P, Sacco PC, Sgambato A, Casaluce F, Rossi A, Gridelli C
- Issue date: 2015 Sep
- Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
- Authors: Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR
- Issue date: 2012 Mar 1